Aspira Pathlab & Diagnostics Limited will hold a board meeting on August 12, 2026, to consider and approve the unaudited financial results for the first quarter ended June 30, 2026, and to evaluate a proposal for raising funds through instruments including equity shares or warrants convertible into equity shares, via preferential issue, private placements, rights issue, or other permitted methods.